Survival analysis and development of a prognostic nomogram for bone‐metastatic prostate cancer patients: A single‐center experience in Indonesia

Afriansyah, Andika; Hamid, Agus Rizal Ardy Hariandy; Mochtar, Chaidir Arif; Umbas, H. Rainy

doi:10.1111/iju.13813

Cited by 14 publications

(15 citation statements)

References 35 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, a Chinese study found that the OS in T3–T4 stages was 61.19%, being lower than in other T stages [31]. Also, a recent study proved that T stage was a prognostic factor for OS [9]. In addition to this, men with PCa who underwent surgery but not chemotherapy/radiation had a better survival than others.…”

Section: Discussionmentioning

confidence: 99%

“…It is based on a number of histopathological end points, including lymphovascular space invasion by carcinoma, tumor size, positive surgical margins, and pathological stage, including risk of extraprostatic extension [8]. In addition to this, several studies have assessed the prognostic value of many other clinical and molecular factors including prostate-specific antigen (PSA), tumor volume, vascular invasion, tumor extension through the prostate capsule, invasion to the seminal vesicle, and circulating biomarkers [5, 9]. It is important to know that the metastasis accounts for about 90% of the cancer deaths [10].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Examined and Positive Lymph Node Counts Are Associated with Mortality in Prostate Cancer: A Population-Based Analysis

et al. 2020

View full text Add to dashboard Cite

Background: Prostate cancer (PCa) is the third leading cause of death from cancer in the United States. We aimed to disclose the prognostic values of examined (dissected) lymph node (ELN), negative lymph node (NLN), and positive (metastatic) lymph node (PLN) counts and lymph node (LNs) ratio in PCa patients. Methods: We extracted data of PCa patients diagnosed between 2004 and 2015 from the Surveillance, Epidemiology, and End Results (SEER) program. We included patients with a histologically confirmed diagnosis having at least one ELN and with the PCa as the primary tumor only. Results: We have included 96,064 patients. Multivariable Cox proportional hazards regression models disclosed that patients having more ELNs were associated with better survival. However, we demonstrated that patients having more PLNs were associated with worse survival. Additionally, older age, unmarried patients, with Gleason's score of 8-10, T4 and M1 stages and those who received chemotherapy and/ or radiation but did not receive surgery were significantly associated with worse PCa survival. Conclusions: We have disclosed several independent predictors affecting PCa patients including age, marital status, Gleason's score, T and N stages, having received therapy, surgery, and ELN and PLN counts. Moreover, we demonstrated that patients with lower ELN and higher PLN counts were a high-risk group. We strongly recommend adding the ELN and/or PLN counts into consideration during patient staging/treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Examined and Positive Lymph Node Counts Are Associated with Mortality in Prostate Cancer: A Population-Based Analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…[7] At present, the independent prognostic factors for bone metastatic PCa remain controversial and there are significant differences in OS between studies. [8,9] It should also be noted that prostate-specific antigen (PSA) values were >20 ng/ml in over 90% patients with bone metastatic PCa, which means almost all patients enter the D’Amico high-risk stage when bone metastases are present. [3] Therefore, nomograms based on the equation derived from the regression coefficients of each variable always integrates many prognostic factors may better predict their survival.…”

Section: Introductionmentioning

confidence: 99%

Development and validation of a SEER-based prognostic nomogram for patients with bone metastatic prostate cancer

et al. 2019

View full text Add to dashboard Cite

Controversies exist between the previous two prognostic nomograms for patients with bone metastatic prostate cancer (PCa), and a nomogram applied to western patients has yet to be established. Thus, we aimed to build a reliable and generic nomogram to individualize prognosis.The independent prognostic factors were identified in a retrospective study of 1556 patients with bone metastatic PCa registered in the Surveillance, Epidemiology and End Results (SEER) database. Besides, the prognostic nomogram was developed using R software according to the result of multivariable Cox regression analysis. Then, the discriminative ability of the nomogram was assessed by analyses of receiver operating characteristic curves (ROC curves). We also performed 1-, 2-, and 3-year calibrations of the nomogram by comparing the predicted survival to the observed survival. Furthermore, the model was externally validated using the data of 711 patients diagnosed at different times enrolled in the SEER database.Age ≥70 years, Gleason score ≥8, PSA value of 201 to 900 ng/ml, stage T4, stage N1, with liver metastases, and Asian/Pacific ethnicity were identified as independent prognostic factors. In the primary cohort, 1-, 2-, and 3-year area under the ROC curve (AUC) of the nomogram for predicting cancer-specific survival (CSS) were 0.71, 0.70, and 0.70, respectively. Besides 1-, 2-, and 3-year AUC were 0.70, 0.68, and 0.69, respectively, in the external validation cohort. Moreover, calibration curves presented perfect agreements between the nomogram-predicted and actual 1-, 2-, and 3-year CSS rate in both the primary and external validation cohorts. In other words, our nomogram has great predictive accuracy and reliability in predicting 1-, 2-, and 3-year CSS for patients with bone metastatic prostate cancer.This study established and validated a prognostic nomogram applied to not only Asian patients but western patients with bone metastatic PCa, which will be useful for patients’ counseling and clinical trial designing.

show abstract

“…In mCRPC treatment, newly established medications are more expensive than ADT or docetaxel treatment, which eventually affects a country's insurance system [6,21]. Previous studies also created nomograms to predict the prognosis in Chinese CRPC patients [ref].…”

Section: Discussionmentioning

confidence: 99%

The Development and Validation of a Prognostic Nomogram and Nomogram Application Software Among Men Treated with Abiraterone Acetate and/or Enzalutamide for Metastatic Castration-resistant Prostate Cancer

Kawahara

Saigusa

Yoneyama

et al. 2020

Preprint

View full text Add to dashboard Cite

Background:With widespread medication choices for metastatic castration-resistant prostate cancer (mCRPC) is now available, on the other hand biomarker to predict the efficacy of each mCRPC treatment has not been established.Objective:This study developed prognostic nomogram to predict prognosis in CRPC patients who received abiraterone acetate (ABI) and/or enzalutamide (ENZ).Design, Setting, and Participants:A total of 568 mCRPC patients received ABI and/or ENZ from 2012 to 2017 were enrolled in this study. We developed prognostic nomogram based on the risk factors by Cox proportional hazards regression model.Outcome Measurements and Statistical Analysis:The nomogram was also assessed for discriminatory ability with the concordance index (C-index). We repeated 5-fold cross-validation 2000 times to estimate the C-index and reported the means of the estimated C-index for the training and validation sets. And we also developed nomogram application software (app) based on this nomogram.Results and Limitations:The median overall survival (OS) was 24.7 months. A multivariable analysis showed that the time to CRPC, pre-chemotherapy, baseline PSA, baseline ALP, and baseline LDH were independent risk factors for the OS (HR: 0.521, 1.681, 1.439, 1.827, 12,123, p:0.001, 0.001, <0.001, 0.019, <0.001)). C-index was 0.72 in training cohort and 0.71 in validation cohort.Conclusion:We developed nomograms to predict the OS for Japanese mCRPC patients who received ABI and/or ENZ. The advent of mCRPC prognosis prediction app will facilitate greater accessibility for clinical use.Patient SummaryThis study developed and validated a nomogram for predicting the prognosis of mCRPC patients who receive ABI/ENZ treatment using clinical information. This study also developed mobile app to facilitate clinical usage.

show abstract

Survival analysis and development of a prognostic nomogram for bone‐metastatic prostate cancer patients: A single‐center experience in Indonesia

Cited by 14 publications

References 35 publications

Examined and Positive Lymph Node Counts Are Associated with Mortality in Prostate Cancer: A Population-Based Analysis

Examined and Positive Lymph Node Counts Are Associated with Mortality in Prostate Cancer: A Population-Based Analysis

Development and validation of a SEER-based prognostic nomogram for patients with bone metastatic prostate cancer

The Development and Validation of a Prognostic Nomogram and Nomogram Application Software Among Men Treated with Abiraterone Acetate and/or Enzalutamide for Metastatic Castration-resistant Prostate Cancer

Contact Info

Product

Resources

About